FDA Decision Dates: How PDUFA Catalysts Work (2026)

How the PDUFA clock is set

The clock depends on two things: what kind of application it is, and whether the FDA grants priority review.

For a new molecular entity (NME) application or an original biologics license application, the review sits inside what the commitment letter calls "the Program." The FDA first has a 60-day filing review to decide whether the application is complete enough to review. The PDUFA clock starts at the end of those 60 days.

• Standard review: the FDA aims to act on 90 percent of these applications within 10 months of the 60-day filing date. That is about 12 months from submission.
• Priority review: the goal is 6 months from the 60-day filing date, or about 8 months from submission.

For other original applications, such as a new formulation of an approved ingredient (a non-NME application), the clock runs from receipt: 10 months for standard review and 6 months for priority review. Efficacy supplements, which add a new use to an approved drug, follow the same 10-month and 6-month goals from receipt.

The FDA describes priority review as a goal "to take action on an application within 6 months," compared with 10 months under standard review. Priority review goes to drugs that would be significant improvements in treating, diagnosing or preventing serious conditions.

Quick reference: review goals under PDUFA VII

All of these are goals for 90 percent of applications, as stated in the commitment letter. They are performance targets, not guarantees.

The milestones inside a review

A PDUFA review is not silent until the decision. Several dated steps happen in between, and each one can change the picture.

1. Filing decision. Within the 60-day filing review, the FDA decides whether to file the application. An application that is incomplete can get a Refuse-to-File decision, which stops the clock before it starts.
2. Day 74 letter. For applications in the Program, the FDA sends this letter within 74 calendar days of receipt. It lists filing review issues, gives the planned review timeline, including the date of the internal mid-cycle review meeting, and states preliminary plans on whether to hold an advisory committee meeting.
3. Mid-cycle communication. The FDA calls the applicant, generally within two weeks after its internal mid-cycle meeting, to share significant issues found so far and proposed dates for the late-cycle meeting.
4. Advisory committee meeting, if any. When an application goes to an advisory committee, the FDA intends to hold the meeting no later than 2 months before the goal date for a standard review, or 6 weeks before for a priority review.
5. Late-cycle meeting. The FDA and the applicant meet late in the review to discuss major deficiencies and remaining issues. If there is an advisory committee, this meeting comes at least 12 calendar days before it.
6. Action. Approval or a complete response letter, on or before the goal date.

Companies decide how much of this to disclose. Many announce acceptance of the filing and the goal date, and some report whether an advisory committee is planned. The catalyst calendar guide shows how to log each milestone with its source.

What can move the date

The goal date is not fixed once it is set. Three things change it.

A major amendment. If the applicant submits major new information during review, such as a new clinical study report, a major reanalysis of earlier studies, or a new risk management program with restrictive elements, the FDA may extend the goal date by three months. Only one extension is allowed per review cycle. The market often reads an extension as bad news, but it is a timing change, and sometimes it means the FDA asked for more data rather than ending the review with a rejection.

Early action. The goal date is a deadline for the agency, not a release date. The FDA can act before it.

A missed goal. The goals cover 90 percent of applications. The FDA can miss a date, especially when inspections or other outside factors are pending. A missed date with no action leaves the stock in an open state that is hard to price.

The two outcomes

At the goal date, the FDA either approves the application or issues a complete response letter (CRL).

Under 21 CFR 314.110, a CRL describes all the specific deficiencies the FDA has found and, when possible, recommends what the applicant could do to put the application in condition for approval. After a CRL, the applicant must do one of three things: resubmit the application, withdraw it, or request an opportunity for a hearing.

A resubmission starts a new review cycle. The FDA classifies it as Class 1, with a 2-month goal, or Class 2, with a 6-month goal. Class 1 covers minor items, such as labeling, while Class 2 covers anything more substantial. A CRL that only asks for labeling changes or a manufacturing fix is a very different event from one that asks for a new trial, which can add years. The content of the letter matters more than the fact of it.

An approval can also come with conditions: a narrower label than the company sought, a boxed warning, a risk program, or post-marketing study requirements. An approval under the accelerated approval pathway, which relies on a surrogate endpoint, also requires confirmatory trials, and the FDA can withdraw approval or narrow the use if those trials do not verify benefit.

Advisory committees as a signal

An advisory committee is a panel of outside experts that reviews an application in a public meeting and votes on questions the FDA poses. The FDA describes these votes as nonbinding recommendations: the agency generally follows them but is not legally bound to do so.

For investors, the meeting is often the most informative event before the decision. The FDA's briefing documents, posted before the meeting, show the reviewers' concerns in their own words. The questions the agency chooses to ask show where it sees risk. A vote that goes against the FDA reviewers' view, or a split vote, widens the range of outcomes rather than narrowing it.

How investors frame a PDUFA catalyst

A PDUFA date is a hard catalyst on timing: it has a known or bounded date. The outcome is binary at first glance but has a range within each branch. Framing it well means valuing each branch separately.

The arithmetic is simple. The hard parts are the inputs:

• The probabilities. These come from the review signals: the Day 74 letter if disclosed, whether an advisory committee was planned and how it voted, any extension, and the strength of the trial data.
• The CRL value. This depends on cash. A company that needs a new trial must fund it. Check how many quarters of cash remain, as in how to estimate cash runway, and whether the company would have to raise equity at a low price.
• The options market. Option prices before a binary event carry high implied volatility, which collapses once the outcome is known. The IV crush article explains the mechanism, which works the same way around an FDA decision as around earnings.

A short decision list for reading the setup:

• If the company has not disclosed a goal date, treat any third-party date as an estimate until you find it in a filing.
• If an advisory committee was planned and then cancelled, read the company's explanation closely; it can point either way.
• If the goal date was extended after a major amendment, find what was submitted and whether the FDA asked for it.
• If the company's cash covers less than a year after a CRL, the CRL branch is worth less than the science alone suggests.

Dombey's published research tracks dated catalysts like these alongside cash and dilution risk; see the research archive.

Where this goes wrong

PDUFA catalysts look tidy on a calendar. In practice, several things break the model.

• The date is not the decision. The FDA can act early, late, or extend. A position sized for a specific day can sit for months longer than planned.
• Binary outcomes punish sizing errors. A single CRL can cut a single-product company's value by half or more. No amount of research removes that tail.
• The approval can still disappoint. A narrow label, a boxed warning or a restrictive risk program can leave the stock lower after approval if the market priced a broad label.
• Financing follows approval. Many small companies raise equity soon after approval to fund a launch. The dilution can offset part of the gain.
• Information is uneven. The company sees FDA communications that it may not disclose in full. A quiet company before its goal date is not necessarily a confident one.
• Third-party calendars contain errors. Dates get copied between sites and go stale after extensions. The company's own filings are the source of record.

The bottom line

A PDUFA date is the FDA's goal date to act on a drug or biologic application, set by the review goals in the PDUFA VII commitment letter: 10 months for standard review and 6 months for priority review, measured from the 60-day filing date for new molecular entities and from receipt for most others. The date can move by three months after a major amendment, and the action is either an approval or a complete response letter. Treat the date as a hard catalyst with a wide, uncertain outcome, value each branch separately, and check the cash position before assuming a company can survive a rejection. As with any stock catalyst, the date tells you when, not what.